IgG4 Related Disease Clinical Trial
Official title:
A Phase II, Single-Site, Open-Label Study of Zanubrutinib in Patients With IgG4-Related Disease
The aim of this clinical trial is to evaluate the safety and efficacy of zanubrutinib in treating patients with IgG4-related disease
This will be a single-site, open-label study in symptomatic patients with IgG4-related disease affecting the submandibular and/or lacrimal glands. All patients will receive zanubrutinib orally at a dose of 80mg BID for 24 weeks. The primary objective of this study is to demonstrate that zanubrutinib treatment reduces reduces the volume of the submandibular and/or lacrimal glands on PET/MRI at week 24 compared to baseline. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05662241 -
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
|
Phase 3 | |
| Active, not recruiting |
NCT04540497 -
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
|
Phase 3 | |
| Terminated |
NCT04918147 -
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
|
Phase 2 | |
| Completed |
NCT04817553 -
Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients
|
||
| Not yet recruiting |
NCT05728684 -
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
|
N/A | |
| Recruiting |
NCT06361745 -
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
|
N/A |